Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Trivalent COVID-19 Vaccine (Vero Cell), Inactivated, Prototype Strain, Delta Strain and Omicron Strain
- Development stage
- Phase 3
- Lead developer
- Sinovac Life Sciences
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Trivalent COVID-19 Vaccine (Vero Cell), Inactivated, Prototype Strain, Delta Strain and Omicron Strain is an inactivated, alum-adjuvanted whole-virion SARS-CoV-2 vaccine developed by Sinovac Life Science to broaden protection against COVID-19 by incorporating antigens from the ancestral prototype strain and the Delta and Omicron variants.[12] The vaccine is produced by propagating each SARS-CoV-2 strain in Vero cells, chemically inactivating the viruses, purifying and formulating them with aluminum-based adjuvant to enhance immunogenicity, thereby inducing neutralizing antibodies and cellular immune responses against multiple variants of concern.[12] It is being evaluated primarily as a booster dose in individuals previously vaccinated against COVID-19, with clinical development focused on immunogenicity and safety outcomes rather than naïve primary series use.[12]
- Other names
- Trivalent COVID-19 Vaccine (Sinovac)Trivalent COVID-19 Vaccine (Vero Cell), InactivatedTrivalent COVID-19 Vaccine (Vero Cell), Inactivated, Prototype Strain, Delta Strain and Omicron Strain
Beyond the preview
Go deeper on Trivalent COVID-19 Vaccine (Vero Cell), Inactivated, Prototype Strain, Delta Strain and Omicron Strain.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Trivalent COVID-19 Vaccine (Vero Cell), Inactivated, Prototype Strain, Delta Strain and Omicron Strain.